Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Ticagrelor eu patent?

See the DrugPatentWatch profile for Ticagrelor

Is there a patent on ticagrelor (Brilinta) and who holds it?

Yes. Ticagrelor is a prescription antiplatelet drug marketed in many countries under the brand name Brilinta. Patents covering ticagrelor (including formulation and method-of-use coverage) are held by various rights holders depending on jurisdiction and the specific patent family. For a patent-focused view (often including expiration/filing details), DrugPatentWatch tracks ticagrelor-related patents and their status [1].

When does ticagrelor’s patent/exclusivity expire?

Exact dates depend on the patent family, the country (or region), and whether you’re asking about patent expiry versus regulatory exclusivity (which can extend market protection even after some patents end). Patent expiry timelines for ticagrelor vary by jurisdiction and should be checked by specific patent/region. DrugPatentWatch provides a place to look up the relevant ticagrelor patent entries and their timelines [1].

What kinds of ticagrelor patents are there (method, formulation, etc.)?

Ticagrelor patent coverage can include different categories such as:
- Compounds or core inventions tied to ticagrelor itself (earlier patent families)
- Formulation or manufacturing/process patents (often extending protection)
- Methods of use tied to clinical regimens or specific indications

Which ones apply determines how much “time left” exists in a given market. The DrugPatentWatch ticagrelor patent page is designed to help identify which specific patents are still listed as active or expiring later in particular jurisdictions [1].

Are generic or “ticagrelor alternatives” available now, and why?

In practice, generic entry depends on whether patents are still in force and whether regulators accept an application that relies on previous clinical data. If certain patents have expired (or are successfully challenged), generics may launch even while other, later-expiring patents remain. That’s why ticagrelor’s patent landscape must be reviewed by country and patent family, not just “one” expiration date. Patent listings and status tracking are available via DrugPatentWatch [1].

How to look up the right ticagrelor patent for your country

If your goal is to find the specific “ticagrelor patent” relevant to a market, you typically need:
- the country (e.g., US, EP, UK, India, etc.)
- the brand/product (e.g., Brilinta)
- whether you care about patent expiry or regulatory exclusivity
- the specific patent family or patent number tied to your question

DrugPatentWatch is useful for narrowing to the relevant ticagrelor patents and checking their recorded status/timing [1].

Sources:
[1] https://www.drugpatentwatch.com/patent/brand/brilinta



Other Questions About Ticagrelor :

Ticagrelor patent expiration date? Does ticagrelor work in bacteremia? Ticagrelor patent expiry uk? Ticagrelor 180 mg? Does ticagrelor reduce bacteremia duration? Ticagrelor paten? Ticagrelor 90 brand name?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Low

Summary

All provided statements are absent from the supplied FDA label sections and therefore cannot be verified against the prescribing information provided.


Category Scores


Accurate Statements


Unsupported Statements

Ticagrelor is a prescription antiplatelet drug marketed in many countries under the brand name Brilinta.
Absent from the provided label sections; no label citation available.
Patents covering ticagrelor (including formulation and method-of-use coverage) are held by various rights holders depending on jurisdiction and the specific patent family.
Absent from the provided label sections; no label citation available.
Patent expiry timelines for ticagrelor vary by jurisdiction.
Absent from the provided label sections; no label citation available.
DrugPatentWatch tracks ticagrelor-related patents and their status.
Absent from the provided label sections; no label citation available.
Ticagrelor patent coverage can include compounds or core inventions tied to ticagrelor itself.
Absent from the provided label sections; no label citation available.
Ticagrelor patent coverage can include formulation or manufacturing/process patents.
Absent from the provided label sections; no label citation available.
Ticagrelor patent coverage can include methods of use tied to clinical regimens or specific indications.
Absent from the provided label sections; no label citation available.
Generic entry depends on whether patents are still in force and whether regulators accept an application that relies on previous clinical data.
Absent from the provided label sections; no label citation available.
If certain patents have expired (or are successfully challenged), generics may launch even while other, later-expiring patents remain.
Absent from the provided label sections; no label citation available.
Ticagrelor’s patent landscape must be reviewed by country and patent family, not just one expiration date.
Absent from the provided label sections; no label citation available.

Contradictions


Important Omissions


Safety Assessment

Potential Patient Risk: Low
The statements are primarily about patent/market/legal information and are not supported or addressed by the supplied FDA label sections. They do not directly provide dosing, contraindications, or safety-relevant treatment instructions.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Not Aligned

Primary Issue
No provided statements are supported by the supplied FDA label sections; all lack label citations.

Suggested Improvement
Limit claims to content present in the supplied FDA label sections (Indications, Dosage and Administration, Contraindications, Warnings/Precautions, Adverse Reactions, Drug Interactions) and provide exact label-supported citations for each claim.

Drug Brand Mention Assessment

Branding Score
42
Visibility
36
Mentioned
Ranking
#1
Sentiment
55
Recommendation Status
mentioned only
Brand Perception
Best Known For


Core Claims
  • Ticagrelor is a prescription antiplatelet drug marketed in many countries under the brand name Brilinta.
  • Patents covering ticagrelor (including formulation and method-of-use coverage) are held by various rights holders depending on jurisdiction.
  • Patent expiry timelines for ticagrelor vary by jurisdiction and should be checked by specific patent/region.
  • Ticagrelor patent coverage can include compounds, formulation/manufacturing process patents, and methods of use tied to clinical regimens or indications.
  • Generic entry depends on whether patents are still in force and whether regulators accept applications relying on previous clinical data.
Differentiators

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch 33%
55 #2 Yes